Real World Evaluation of Sotorasib Among Chinese Non-Small Cell Lung Cancer Patients

Summary

The primary objective of this study is to characterize the safety profile of sotorasib.

Eligibility

Inclusion Criteria:

* Adult (≥ 18 years) as of the index date.
* KRAS p.G12C-mutated locally advanced or metastatic NSCLC.
* Received at least 1 dose of sotorasib.
* Receipt of at least 1 prior systemic therapy before use of sotorasib.
* Obtained ICF, if required.

Exclusion Criteria:

* Documentation of being a non-Chinese ethnicity.

Conditions3

Interventions1

Related trials

• Clinical Trial of AMG510 in Stage III Unresectable NSCLC KRAS p.G12C Patients and Ineligible for Chemo-radiotherapy — Fundación GECP
• ERectile Dysfunctions, gOnadotoxicity and Sexual Health Assessment in Men With Lung Cancer — Fondazione Policlinico Universitario Agostino Gemelli IRCCS
• Pre-operative Targeted Treatments in Molecularly Selected Resectable Colorectal Cancer (UNICORN) — Gruppo Oncologico del Nord-Ovest
• Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial — National Cancer Institute (NCI)
• Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Participants With Metastatic Colorectal Cancer With KRAS p.G12C Mutation — Amgen
• Carfilzomib in Combination With Sotorasib for the Treatment of Patients With KRAS G12C Mutated Advanced or Metastatic Non-small Cell Lung Cancer — City of Hope Medical Center
• Study of eFT226 in Subjects With Selected Advanced Solid Tumor Malignancies — Effector Therapeutics
• Sotorasib in Combination With Trastuzumab Deruxtecan for the Treatment of Locally Advanced and Metastatic Non-small Cell Lung Cancer With a KRAS G12C Mutation — National Cancer Institute (NCI)

Browse More Trials